Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia

The incidence of serum sickness following treatment of CLL with obinutuzumab has not been fully characterized, but is likely rare. Consideration should be given to this diagnosis in appropriate circumstances so that effective corticosteroid therapy can be initiated to alleviate inflammatory symptoms...

Descripción completa

Detalles Bibliográficos
Autores principales: Saba, Julie, Logan, Aaron C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457998/
https://www.ncbi.nlm.nih.gov/pubmed/28588833
http://dx.doi.org/10.1002/ccr3.969
Descripción
Sumario:The incidence of serum sickness following treatment of CLL with obinutuzumab has not been fully characterized, but is likely rare. Consideration should be given to this diagnosis in appropriate circumstances so that effective corticosteroid therapy can be initiated to alleviate inflammatory symptoms and organ dysfunction in a timely manner.

Ejemplares similares